Lactobacillus reuteri
A probiotic species that lives in the human gut. Strain RC-14, paired with L. rhamnosus GR-1, has the most research for vaginal flora balance.
- Part used
- Whole live bacteria
- Also called
- L. reuteri, Limosilactobacillus reuteri
- In our formulas
- 3
- Studies cited
- 5
What it is
Lactobacillus reuteri is a lactic acid bacterium found naturally in the human gut, mouth and vagina. Supplements use freeze-dried cultures counted in colony-forming units (CFU).
Effects depend on the strain. The most studied vaginal strain is RC-14, almost always tested together with L. rhamnosus GR-1. The evidence below is for that pair, not for L. reuteri in general. We do not know which strains a given blend uses unless the label names them.
What the research says
-
Some human studies
Supports a healthy balance of vaginal flora.*
These trials all gave RC-14 with GR-1 by mouth, most alongside antibiotics. In 64 women, 4 weeks of the pair left 75% with normal flora against 34% on placebo; in 125 women, 1 billion CFU of each twice daily for 30 days left 88% with normal flora and no symptoms against 40%. In 72 postmenopausal women, 2.5 billion of each daily for 14 days improved flora scores in 60% against 16%. But a 126-woman trial found no added benefit, and in 238 pregnant women the pair did not change vaginal flora at all1,2,3,4,5.
What to look for on a label
Check the label names the strain (RC-14 or another designation) as well as the species.
The trials gave about 1 to 2.5 billion CFU of each strain once or twice a day for 14 to 30 days. Blend totals on labels often do not show the amount of each strain.
Choose a product that guarantees CFU through the expiry date.
How First Organic uses it
Three of our formulas contain L. reuteri: Fembiotic+ and Intimatease+, in a 10 billion CFU Vaginal Probiotic Blend of 5 strains, and Menopease+, in a 5 billion CFU Probiotic Blend. Each label lists it by species, Lactobacillus reuteri, without naming the strain.
The labels give one total per blend, not a count for each strain. So we cannot claim that a serving matches the RC-14 and GR-1 doses in the trials above, and those results belong to that strain pair.
| Formula | Per serving |
|---|---|
| Fembiotic+ | in the vaginal probiotic blend (5 strains), 10 billion cfu |
| Intimatease+ | in the vaginal probiotic blend (5 strains), 10 billion cfu |
| Menopease+ | in the probiotic blend, 5 billion cfu |
Amounts are from each product's supplement facts panel. "In the blend" means the label gives one total for a group of ingredients.
Before you take it
Usually well tolerated. Temporary gas or bloating can occur. People with weakened immune systems or serious illness should ask a doctor first. Pregnant or breastfeeding women should check with their clinician.
References
-
1
Martinez RC, Franceschini SA, Patta MC, et al. Improved cure of bacterial vaginosis with single dose of tinidazole (2 g), Lactobacillus rhamnosus GR-1, and Lactobacillus reuteri RC-14: a randomized, double-blind, placebo-controlled trial Canadian journal of microbiology, 2009. randomised trial
-
2
Anukam K, Osazuwa E, Ahonkhai I, et al. Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial Microbes and infection, 2006. randomised trial
-
3
Petricevic L, Unger FM, Viernstein H, et al. Randomized, double-blind, placebo-controlled study of oral lactobacilli to improve the vaginal flora of postmenopausal women European journal of obstetrics, gynecology, and reproductive biology, 2008. randomised trial
-
4
Zhang Y, Lyu J, Ge L, et al. Probiotic Lacticaseibacillus rhamnosus GR-1 and Limosilactobacillus reuteri RC-14 as an Adjunctive Treatment for Bacterial Vaginosis Do Not Increase the Cure Rate in a Chinese Cohort: A Prospective, Parallel-Group, Randomized, Controlled Study Frontiers in cellular and infection microbiology, 2021. randomised trial
-
5
Husain S, Allotey J, Drymoussi Z, et al. Effects of oral probiotic supplements on vaginal microbiota during pregnancy: a randomised, double-blind, placebo-controlled trial with microbiome analysis BJOG : an international journal of obstetrics and gynaecology, 2020. randomised trial
* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. This guide is general information, not medical advice.